Post sponsored by NewzEngine.com

Source: Pharmac

What we’re doing

We are pleased to announce the approval of a listing agreement with O&M Halyard Australia Limited for listing of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020.

We will list medical devices in the following categories:

  • continence products; and
  • surgical drapes, gowns and procedure packs.

In summary this will result in:

  • O&M Halyard’s medical devices, in the categories above, being listed in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020 under a national agreement that all DHBs may purchase under (“Agreement”); and

  • DHBs being able to continue to purchase other suppliers’ brands of surgical drapes and gowns and continence products as the Agreement is not for sole supply.

Details about this decision

In 2018 PHARMAC issued Requests for Proposals (“RFPs”) for:

These RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with O&M Halyard, PHARMAC has decided to list O&M Halyard’s medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020.

The list of products will be available on PHARMAC’s website from 1 February 2020, in both a PDF document and an Excel spreadsheet.

DHBs can continue to choose which surgical drapes and gowns, and continence products they purchase, including those from other suppliers. DHBs that purchase medical devices in the categories above, from O&M Halyard, must do so under the terms and conditions, including pricing, in the Agreement, from 1 February 2020.

The Agreement includes terms and conditions for training and education to be provided by O&M Halyard on the appropriate use of its products, which is to be provided at times as agreed with individual DHBs.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:

Theme

Comment

No technical or resource impacts anticipated as a result of the proposal.

Noted.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.

Last updated: 9 December 2019

MIL OSI